WAM
IBIO icon

Warberg Asset Management’s iBio IBIO Stock Holding History

Warberg Asset Management’s Portfolio IBIO Stock Details IBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-19,000
Closed -$26.2K – 228
2023
Q4 		$26.2K Buy
+19,000
New +$83K 0.01% 148
2023
Q1 		– Sell
-2,500
Closed -$22.2K – 263
2022
Q4 		$22.2K Buy
+2,500
New +$84.6K ﹤0.01% 176

Other funds holding IBIO

OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Warberg Asset Management's IBIO Position: Q1 2024 in Review

Warberg Asset Management sold out of iBio (IBIO) in Q1 2024, closing a stake of 19,000 shares — an estimated $26.2K sold.

Warberg Asset Management first reported a position in IBIO in Q4 2022 and held it in 2 quarters. The position peaked at $26.2K in Q4 2023. 28 funds tracked by Wall St. Rank hold IBIO as of Q1 2024.

  • Warberg Asset Management reported no remaining iBio position as of Q1 2024 after selling out during the quarter.
  • Warberg Asset Management sold 19,000 iBio shares in Q1 2024, an estimated $26.2K.
  • Warberg Asset Management first reported a position in iBio in Q4 2022 and held it in 2 quarters.
  • Warberg Asset Management's iBio position peaked at $26.2K in Q4 2023.
  • 28 funds tracked by Wall St. Rank held iBio as of Q1 2024.

Based on Warberg Asset Management's 13F filing for Q1 2024, filed 6 May 2024.